Laura Kight
Psychiatric/Mental Health · Lafayette, LANPI 1205351137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,026, 4.7 times the $646 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$926
- Braeburn Inc.$829
- Indivior Inc.$631
- Orexo US, Inc.$595
- Alkermes, Inc.$514
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,795100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $1,838 |
| Johnson & Johnson | 33 | $926 |
| Braeburn Inc. | 38 | $829 |
| Indivior Inc. | 38 | $631 |
| Orexo US, Inc. | 38 | $595 |
| Alkermes, Inc. | 27 | $514 |
| Vanda Pharmaceuticals Inc. | 18 | $513 |
| Neurocrine Biosciences, Inc. | 16 | $423 |
| Teva Pharmaceuticals USA, Inc. | 14 | $330 |
| Axsome Therapeutics, Inc. | 10 | $305 |
| E.r. Squibb & Sons, L.L.C. | 4 | $260 |
| AstraZeneca | 2 | $220 |
| Abbott | 1 | $146 |
| Novo Nordisk | 2 | $135 |
| Avanir Pharmaceuticals, Inc. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $119 |
| Idorsia Pharmaceuticals US Inc | 1 | $104 |
| Regeneron Healthcare Solutions, Inc. | 1 | $103 |
| Phathom Pharmaceuticals, Inc. | 1 | $95 |
| Gilead | 1 | $95 |
| Sage Therapeutics, LLC | 1 | $93 |
| Pfizer | 1 | $82 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| Corium, LLC | 6 | $71 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $51 |
| Lundbeck LLC | 1 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,800 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $98,300 |
| VraylarCariprazine Hcl | 23 | $40,367 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 104 | $30,733 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $10,153 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,402 |
| Lamotrigine ErLamotrigine | 19 | $5,094 |
| Buprenorphine Hcl | 65 | $2,653 |
| Vilazodone Hcl | 12 | $2,154 |
| Quetiapine Fumarate | 72 | $1,090 |
| Duloxetine Hcl | 46 | $1,053 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $671 |
| Buspirone Hcl | 30 | $650 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 32 | $535 |
| Prazosin Hcl | 32 | $479 |
| Oxcarbazepine | 15 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $423 | $98,30012 claims |
| AbbVieVraylar | $1,838 | $40,36723 claims |
| Indivior Inc.Suboxone | $631 | $10,15315 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $33 | $6,40217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lafayette
- Melissa GuilbeauLafayette$122K
- Bryant DronetteLafayette$17K
- Cinderella BroussardLafayette$14K
- Lore Lyndsey MoranLafayette$12K
- Danielle ThreattsLafayette$11K
- Seth WoodruffLafayette$10K
- Latonya WoodsLafayette$10K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.